Aclasta, Veclade get CHMP nods

The European Medicines Agency's drug-review committee got busy today issuing recommendations--and rejections--for a laundry list of new meds and new indications for old ones. Here are the highlights.

  • Novartis' bone drug Aclasta got the nod for treating men at increased risk of fracture, including those with a recent low-trauma hip fracture. It's currently approved only for use in post-menopausal women and for treatment of Paget's disease.
  • Johnson & Johnson's blood cancer med Velcade got a thumbs-up for a new indication: use in combination with melphalan and prednisone in previously untreated multiple myeloma patients who aren't eligible for high-dose chemo. Velcade is already approved as monotherapy for patients who've tried at least one other treatment.
  • Bayer's anticlotting medicine Xarelto--one of its leading drug hopefuls--got the committee's blessing for preventing clots after surgery.
  • Sanofi-Aventis' attempt to broaden use of its cancer meds Taxotere and Docetaxel Winthrop failed to get CHMP's OK; both meds are already approved for breast cancer treatment in combination with other anticancer meds.

As you know, a committee decision isn't guaranteed to be ratified by the EMEA itself, but it generally is.

- see the roundup from CNN Money

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.